Allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia

Cancer Treatment and Research

Volumn 144, Issue , 2009, Pages 441-454

  Weisdorf, Daniel ^a   Forman, Stephen ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RADIATION DOSE; RECURRENCE RISK; REVIEW;

EID: 77953656837     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78580-6_18     Document Type: Review

References (75)

1. Gökbuget N, Noelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2006;133-141
2. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99:863-871
3. Goldstone AH, Richards SH, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplant is less effective than conventional consolidation maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111:1827-1833.
4. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 54:166-178
5. Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002;16:1259-1266
6. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995;85:2025-2037
7. Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123-131
8. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760-3767
9. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL BFM90: German-Austrian Swiss ALL BFM Study Group. Blood 2000; 95:3310-3322
10. Silverman LB, Gelber RD, Dalton VK, et al. Approved outcome for children with acute lymphoblastic leukemia: results of Dana Farber Consortium protocol 91-01. Blood 2001;97:1211-1218
11. Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukemia.MRCUKALLXandXAcompared: a report from the MRC Paediatric and Adult Working Parties. Leukemia 1998;12:463-473
12. Boissel N, Auclerc MF, Lhéritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-780
13. Sandler DP, Ross JA. Epidemiology of acute leukemia in children and adults. Semin Oncol. 1997;24:3-16.
14. Sali D, Cardis E, Sztanyik L, et al. Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Int J Cancer. 1996;67:343-352
15. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165-169
16. Ferrando AA, Look AT. Pathobiology of acute lymphoblastic leukemia. In: Hoffman, R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Hematology. Basic principles and practices, 4th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 1135-1154
17. Pullarkat VA, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group study SWOG-9400. Blood 2008;111:2563-2572
18. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189-3197
19. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103:4396-4407 (Pubitemid 38745962)
20. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108:1469-1477
21. Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer 2007;109:2068-2076
22. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357-2366
23. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome- positive acute lymphoblastic leukemia. Blood 2005;105:3449-3457
24. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:2791-2793
25. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101: 2788-2801
26. Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:1094-1104
27. Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107:1116-1123
28. Raff T, Gokbuget N, Luschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007;109:910-915
29. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007;21:622-626
30. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075-4086 (Pubitemid 41185176)
31. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high dose therapy and autologous BMT: a GOELAMS trial. Blood 2004; 104:3028-3037
32. Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French protocol LALA87. Hematol Oncol Clin North Am. 2000;14:1353-1366
33. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stemcell transplantation in adult patients with acute lymphoblastic leukemia: no difference in relation compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22:2816-2825
34. Yanada M, Matsuo K, Suzuki T, et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006;106:2657-2663
35. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995;86:1619-1628
36. Thiebaut A, Vernanr JP, Degos L, Huguet FR, Reiffers J, Debban C, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA.Hematol Oncol Clin North Am. 2000;14:1353-1365
37. Labar B, Suciu S, Zittoun R, Muus P, Marie JP, Fillet G, et al., EORTC Leukemia Group. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non- Hodgkin's lymphoma for patients
38. Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol. 2002;20:4655-4664 (Pubitemid 36025282)
39. Gupta V, Yi QL, Brandwein J, Minden MD, Schuh AC, Wells RA, et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant. 2004;33:397-404.
40. Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation: multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant. 1991;7:453-459
41. Blume KG, Forman SJ, Snyder DS, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission. Transplantation. 1987; 43:389-392
42. Vernant JP, Marit G, Maraninchi D, et al. Allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia in first complete remission. J Clin Oncol. 1988;6:227-231 (Pubitemid 18065926)
43. Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol. 1994;12:2580-2587
44. Vey N, Blaise D, Stoppa AM, et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant. 1994;14:383-388
45. MarksDI, PerezWS, He W, et al.Unrelated donor transplants in adults with Philadelphianegative acute lymphoblastic leukemia in first complete remission. Blood 2008; 112:426-434
46. Bachanova V, Weisdorf D. Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review. Bone Marrow Transplant. 2008;41:455-464
47. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001;97:1572-1577
48. Weisdorf D, Bishop M, Dharan B, Bolwell B, Cahn JY, Cairo M, et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002;8:213-220 (Pubitemid 34520536)
49. Barker JN,WeisdorfD,Wagner JE. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med. 2001;24:1870-1881
50. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006;38:421-426
51. Bishop MR, Logan BR, Gandham S, et al. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008; 41:635-642
52. Garderet L, Labopin M, Gorin NC, Polge E, Fouillard L, Ehringer GE, et al. Patients with acute lymphoblastic leukemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant. 2003;31:23-29
53. Dahlke J,Kröger N, Zabelina T,Ayuk F, Fehse N,Wolschke C, et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant. 2006;37:155-163
54. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265-2275
55. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276-2285
56. Cornetta K, Laughlin M, Carter S, Wall D, Weinthal J, Delaney C, et al. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant. 2005;11:149-160 (Pubitemid 40186212)
57. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Singleinstitute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004;104: 3813-3820
58. Tomblyn MB, DeFor TE, Tomblyn MR, MacMillan M, Higgins PD, Dusenbery KE, et al.Hematopoietic cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL): 25-year experience at the University of Minnesota. J Clin Oncol. 2007;25(Suppl 185):3575.
59. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562
60. Appelbaum FR. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Leukemia 1997;11:S15-S17.
61. Weisdorf DJ, Nesbit ME, Ramsay NKC, Woods WG, Goldman A, Kim TH, Hurd DD, McGlave PB, Kersey JH:Allogeneic bonemarrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associatedwith acute graft vs. host disease. JClin Oncol. 1987;5:1348-1355
62. Passweg JR, Tiberghien P, Cahn JY, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21:153-158
63. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050
64. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444
65. ValcarcelD,Martino R, Sureda A, et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol. 2005;74:144-151
66. Arnold R, Massenkeil G, Bornhaüser M, et al.Nonmyeloablative stemcell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002;16:2423-2428
67. Gutierrez-Aguirre CH,Gomez-Almaguer D, Cantu-RodriguezOG, et al.Non-myeloablative stem cell transplantation in patients with relapsed cute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant. 2007;40:535-539
68. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernández-Avilés F, San Miguel J, Sierra J. Allogeneic hematopoietic stem cell transplantation with reducedintensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003;88:555-560
69. Stein A, O'Donnell M, Snyder D, et al. Reduced-intensity stem cell transplantation for high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2007;13:134.
70. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, Blaise D, Rocha V; Acute Leukemia Working Party; European Group for Blood and Marrow Transplantation. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008;93:303-306
71. Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a South-West Oncology Group study. Blood 1993;81:2187-2193
72. Marks DI, Forman SJ, Blume KG, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006;12:438-453
73. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999;94:1237-1247
74. Wong JY, Liu A, Schultheiss T, et al. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol BloodMarrow Transplant. 2006;12:306-315
75. Lee SJ, Klein JP, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110: 4576-4583